Real-world clinical practice over the last decade shows a gradual shift away from sulfonylureas, aligning with guidelines that favor newer antidiabetic agents.
Supports gradual sulfonylurea de-adoption in T2D; leaves open whether this shift improves outcomes.
These data suggest a consensus, slowly, but increasingly aligning with the current National indications of dismissing SUs for the treatment of T2D. The new drugs for diabetes should represent a preferable choice in all patients who do not have specific contraindications.
No takes yet. Share an insight, caveat, or question.
Baccetti et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: